×
About 6,110 results

ALLMedicine™ Advanced Prostate Cancer Center

Research & Reviews  1,732 results

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT01867333

Jul 1st, 2022 - Background: Enzalutamide is a well-tolerated, modern androgen receptor antagonist (ARA) with more enhanced anti-tumor activity compared to previous ARAs. Phase III trial has demonstrated a 4.8 month improvement in survival and a 37% risk reduction...

Assessing the correlation between second progression-free survival (PFS2) and overall s...
https://doi.org/10.1080/03007995.2022.2096353
Current Medical Research and Opinion; Shiota M, De Moor R et. al.

Jul 1st, 2022 - To assess the correlation between PFS2 and OS among patients with advanced prostate cancer (PC) in a real-world setting for Japan. This was a retrospective analysis using the Japanese MDV database. Patients with nmCRPC (non-metastatic Castration-R...

CHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AUR...
https://doi.org/10.1158/0008-5472.CAN-22-0631
Cancer Research; Li H, Wang Y et. al.

Jul 1st, 2022 - Clinical studies have shown that subsets of cancer patients achieve a significant benefit from Aurora kinase inhibitors, suggesting an urgent need to identify biomarkers for predicting drug response. Chromodomain-helicase-DNA-binding protein 1 (CH...

A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT05149131

Jul 1st, 2022 - This is an observational study in which patient data from the past on men with metastatic castration-sensitive prostate cancer is studied. Metastatic castration-sensitive prostate cancer (mCSPC) is a type of advanced prostate cancer that has sprea...

see more →

Guidelines  7 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|radiotherapy,

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|diagnostic imaging,radiotherapy,

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  261 results

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT01867333

Jul 1st, 2022 - Background: Enzalutamide is a well-tolerated, modern androgen receptor antagonist (ARA) with more enhanced anti-tumor activity compared to previous ARAs. Phase III trial has demonstrated a 4.8 month improvement in survival and a 37% risk reduction...

A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT05149131

Jul 1st, 2022 - This is an observational study in which patient data from the past on men with metastatic castration-sensitive prostate cancer is studied. Metastatic castration-sensitive prostate cancer (mCSPC) is a type of advanced prostate cancer that has sprea...

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02893917

Jun 30th, 2022 - PRIMARY OBJECTIVE: I. To assess the clinical activity of the combination of cediranib and olaparib, as measured by radiographic progression free survival (rPFS), as compared to olaparib monotherapy in patients with metastatic castration resistant ...

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy)...
https://clinicaltrials.gov/ct2/show/NCT04071236

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of peposertib (M3814) in combination with radium-223 dichloride or in combination with radium-223 dichloride and avelumab in patients with advanced metastatic castrate-resistant ...

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
https://clinicaltrials.gov/ct2/show/NCT03317392

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase 1) II. Evaluate the radiographic progression-free survival (rPFS). (Phase 2) SECONDARY OBJECTIVES: I. E...

see more →

News  433 results

Niraparib Demonstrates Antitumor Activity in Heavily Pretreated mCRPC With BRCA Mutations
https://www.onclive.com/view/niraparib-demonstrates-antitumor-activity-in-heavily-pretreated-mcrpc-with-brca-mutations

Mar 18th, 2022 - The PARP inhibitor niraparib (Zejula) elicited a meaningful overall response rate (ORR) in patients with heavily pretreated metastatic castration-resistant prostate cancer (CRPC) and DNA repair gene defects (DRDs), particularly those with BRCA alt...

Phase 3 KEYLYNK-010 Trial Examining Pembrolizumab/Olaparib in mCRPC to Stop for Futility
https://www.onclive.com/view/phase-3-keylynk-010-trial-examining-pembrolizumab-olaparib-in-mcrpc-to-stop-for-futility

Mar 15th, 2022 - The phase 3 KEYLYNK-001 trial (NCT03834519) evaluating the combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed following chemotherapy and either ab...

Niraparib Plus Abiraterone Acetate/Prednisone Shows Potential as Frontline Option for HRR Gene–Altered mCRPC
https://www.onclive.com/view/niraparib-plus-abiraterone-acetate-prednisone-shows-potential-as-frontline-option-for-hrr-gene-altered-mcrpc

Mar 10th, 2022 - Niraparib (Zejula) plus abiraterone acetate (Zytiga) and prednisone showed encouraging efficacy in the frontline treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations...

Research Backs Abiraterone for Treating Locally Advanced Prostate Cancer
https://www.medscape.com/viewarticle/965566

Dec 24th, 2021 - Abiraterone acetate with prednisolone should be added to standard treatment for men with high-risk non-metastatic prostate cancer, research suggested. Combination therapy was associated with significantly higher rates of metastasis-free survival c...

Loss, Mutation of NCOR2 Likely Fuels Prostate Cancer Progression, Resistance
https://www.medscape.com/viewarticle/965465

Dec 23rd, 2021 - NEW YORK (Reuters Health) - Loss of the NORC2 (nuclear receptor corepressor 2/silencing mediator for retinoid and thyroid hormone receptors) gene could accelerate resistance to androgen deprivation therapy (ADT) in prostate cancer, and novel thera...

see more →

Patient Education  1 results see all →